Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Yahoo! Finance
Research and Development Expenses : Increased to $35.0 million in Q4 and $114.2 million for the full year, reflecting higher clinical trial activities. General and Administrative Expenses : Slightly decreased in Q4 to $11.5 million but rose marginally to $49.9 million for the full year. Interest Income and Other, Net : Grew to $7.8 million in Q4 and $29.2 million for the full year, due to higher yield marketable securities and interest rates. Net Loss : Reported at $39.2 million for Q4 and $136.0 million for the full year 2023. Clinical Updates : Confirmed 98% SVR4 rate in HCV Phase 2 study and over 1,400 COVID-19 patients enrolled in Phase 3 SUNRISE-3 study. Warning! GuruFocus has detected 4 Warning Signs with AVIR. On February 28, 2024, Atea Pharmaceuticals Inc ( NASDAQ:AVIR ) released its 8-K filing , detailing its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Atea Pharmaceuticals Inc is a clinical-stage
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Global Dengue Pipeline Landscape Report 2024: Therapeutic Assessment and Drug Analysis of 20+ Drugs [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewswire
- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
AVIR
Earnings
- 2/28/24 - Miss
AVIR
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 2/28/24 - Form 10-K
- AVIR's page on the SEC website